This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation.

Inclusion criteria

• ✓. Subject must give written informed consent and privacy authorization prior to participation in the study. Female subjects of childbearing potential and male subjects must agree to contraceptive requirements outlined in the informed consent form (ICF).
• ✓. Subject must be willing and able to comply with the study procedures and visit schedules and must be able to follow verbal and written instructions.
• ✓. Male or female subject between 18 to 55 years of age, inclusive, with narcolepsy-cataplexy (confirmation of diagnosis may occur during screening period).
• ✓. Subject's body mass index (BMI) must be at least 16 kg/m2 but no more than 32 kg/m2
• ✓. Subjects on medications for cataplexy (ie, selective serotonin reuptake inhibitors \[SSRIs\], serotonin and norepinephrine reuptake inhibitors \[SNRIs\], norepinephrine reuptake inhibitors \[NRIs\], tricyclic antidepressants \[TCAs\], or Xyrem) and/or EDS associated with narcolepsy (ie, modafinil, armodafinil, or classical stimulants such as methylphenidate and amphetamine), and/or over-the-counter (OTC) medications known to affect sleep-wake functions must washout the prohibited medications during the 2 weeks (or 5 half-lives) prior to BL-1.
• ✓. Subject must have a negative urine drug screen (UDS) for drugs of abuse at the screening visit
• ✓. Male subjects with female partner(s) of childbearing potential must agree to avoid fathering a child and use acceptable methods of birth control from screening until 60 days after the last study drug administration.
• ✓. Female subjects must have a negative serum pregnancy test at screening.

Exclusion criteria